European Union · Question · QUESTION_WRITTEN
E-10-2024-001556
COVID: reasons why the Commission opened its 2024 tender for 146 million doses only to mRNA vaccines, as the AstraZeneca vaccine is cheaper
Introduced
27 August 2024
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
18 October 2024
Records
Official question E-10-2024-001556 from European Union at European Parliament. Dated 27 August 2024. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
5 official files
COVID: why was the Commission’s 2024 call for tenders for the supply of 146 million vaccine doses open only to mRNA vaccines, despite the AstraZeneca vaccine being cheaper?
COVID: why was the Commission’s 2024 call for tenders for the supply of 146 million vaccine doses open only to mRNA vaccines, despite the AstraZeneca vaccine being cheaper?
QUESTION_WRITTEN · EN · 6 September 2024
COVID: why was the Commission’s 2024 call for tenders for the supply of 146 million vaccine doses open only to mRNA vaccines, despite the AstraZeneca vaccine being cheaper?
QUESTION_WRITTEN · EN · 6 September 2024
Answer
QUESTION_WRITTEN_ANSWER · 18 October 2024
COVID: raisons pour lesquelles la Commission a ouvert son appel d’offre 2024 de 146 millions de doses uniquement aux vaccins à ARNm, le vaccin d’AstraZeneca étant moins cher
QUESTION_WRITTEN · FR · 6 September 2024
COVID: raisons pour lesquelles la Commission a ouvert son appel d’offre 2024 de 146 millions de doses uniquement aux vaccins à ARNm, le vaccin d’AstraZeneca étant moins cher
QUESTION_WRITTEN · FR · 6 September 2024
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.